GlassScriptPhysician profile
Pardeep K Sharma
NPI 1588645196
$4,332.81
in general payments reported to CMS, 2019-2025
41 companies · $983 in 2025
The $983 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $289 · 2021: $310 · 2022: $400 · 2023: $751 · 2024: $1,194 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $709.23 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $523.77 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $340.09 | 2021-2025 | |
| Averitas Pharma INC. | $243.59 | 2023-2024 | Qutenza |
| Corcept Therapeutics | $167.40 | 2022-2025 | Korlym |
| Glaxosmithkline, LLC. | $158.77 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $150.88 | 2023-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $146.44 | 2019-2023 | |
| Dexcom, INC. | $143.18 | 2019-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $140.34 | 2023-2025 | Cequr Simplicity |
| Amgen INC. | $136.95 | 2019-2025 | Repatha, Otezla, Tavneos |
| Travere Therapeutics, INC. | $117.42 | 2025 | |
| Vifor Pharma, INC. | $106.97 | 2025 | Veltassa |
| Lilly USA, LLC | $102.88 | 2019-2024 | Mounjaro |
| Pfizer INC. | $102.37 | 2022-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.55 | 2019-2024 | Jardiance |
| Insulet Corporation | $82.08 | 2019-2023 | Omnipod |
| Evoke Pharma, INC. | $75.55 | 2023-2024 | Gimoti |
| Otsuka America Pharmaceutical, INC. | $75.09 | 2024-2025 | Rexulti |
| Opko Pharmaceuticals, LLC | $58.60 | 2023-2024 | Rayaldee |
| Xeris Pharmaceuticals, INC. | $57.93 | 2024-2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $51.31 | 2023-2025 | Gemtesa |
| Kyowa Kirin, INC. | $41.12 | 2023-2025 | |
| Scpharmaceuticals INC. | $39.01 | 2024-2025 | |
| Medtronic, INC. | $38.94 | 2022-2024 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $37.45 | 2022-2025 | Strensiq |
| Novartis Pharmaceuticals Corporation | $37.42 | 2019-2022 | |
| Amphastar Pharmaceuticals, INC. | $35.70 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $33.41 | 2019 | |
| Abbvie INC. | $30.98 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $30.46 | 2023-2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $29.64 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $29.47 | 2021 | |
| Nxstage Medical, INC. | $28.86 | 2021-2025 | Nxstage System One |
| Amarin Pharma, INC. | $28.73 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $21.65 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Paratek Pharmaceuticals, INC. | $20.35 | 2024 | Nuzyra |
| Daiichi Sankyo INC. | $17.12 | 2019 | |
| Nevro Corp. | $15.65 | 2024 | Senza |
| Aurinia Pharma U.S., INC. | $15.10 | 2025 | Lupkynis |
| Valeritas, INC. | $14.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pardeep Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.